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Daline F. S. Araújo1, Gerlane C. B. Guerra2*, Maria Manuela E. Pintado3, Yasmim R.
F. Sousa4, Francesca Algieri5, Alba Rodriguez-Nogales5, Raimundo F. Araújo, Jr6,
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Abstract
This study evaluated the intestinal anti-inflammatory effects of goat whey in a mouse model
of colitis induced by 2,4-dinitrobenzenesulfonic acid that resembles human IBD. At a con-
centration of 4 g/kg/day, the goat whey improved the symptoms of intestinal inflammation,
namely by decreasing the disease activity index, colonic weight/length, and leukocyte infil-
tration. Moreover, goat whey inhibited NF-κB p65 and p38 MAPK signaling pathways and
consequently down-regulated the gene expression of various proinflammatory markers
such as IL-1β, IL-6, IL-17, TNF-α, iNOS, MMP-9, ICAM-1. Also, goat whey increased the
expression of proteins such as mucins, occludin proteins and cytokine signalling suppres-
sors. The immunomodulatory properties of goat whey were also evaluated in vitro using the
murine macrophage cell line Raw 264 and CMT-93 cells derived from mouse rectum carci-
nomas. The results revealed the ability of goat whey to inhibit the production of NO and
reduce IL-6 production in LPS-stimulated cells. In conclusion, goat whey exhibited anti-
inflammatory effects in the DNBS model of intestinal inflammation, and these observations
were confirmed by its immunomodulatory properties in vitro. Together, our results indicate
that goat whey could have applications for the treatment of IBD.
Introduction
Inflammatory bowel disease (IBD) is a group of chronic inflammatory bowel conditions,
including Crohn’s disease and ulcerative colitis, which are caused by an excessive immune sys-
tem response. The most important symptom is chronic inflammation of the gastrointestinal
tract with periods of exacerbation followed by intervals of remission [1,2]. IBD is associated
with an increase in pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, IL-17,
tumour necrosis factor (TNF)-α, prostaglandins and nitric oxide (NO), which may impair
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colonic muscle contraction and barrier function. These inflammatory mediators are important
for the generation and maintenance of inflammation [3,4].
Activation of Mitogen Activated Protein Kinases (MAPK) pathway has been implicated in
the pathogenesis of IBD. Activated MAPKs can bind and stimulate other kinase targets, trans-
locate to the nucleus and activate transcription of pro-inflammatory genes. One of the well-
studied components of MAPK signaling pathway is the nuclear transcription factor kappa B
(NF-kB), which strongly influences the course of mucosal inflammation [5,6]. Activation of
NF-κB can be initiated by different stimuli including bacterial cell wall components such as
lipopolysaccharides, pro-inflammatory cytokines, viruses and DNA damaging agents [7].
The current pharmacological treatments for IBD include 5-aminosalicylic acid, azathio-
prine, mercaptopurines, cyclosporine and corticosteroids [8,9]. The introduction of biological
treatments such as monoclonal anti-TNF-α antibodies, which have demonstrated clinical effi-
cacy, represents a major recent advance in IBD therapy, but these treatments also increase the
risk of infection and hypersensitivity [10,11]. Although these pharmacological innovations
have improved the quality of life of patients, the induction of remission of the disease is accom-
panied by side effects caused by the drugs [12,13].
As an alternative or a complement to pharmacological treatments, the effects of functional
foods have been extensively studied, and some contain compounds that possess intestinal anti-
inflammatory activity. In this sense, goat milk and its derivatives are promising functional
foods for health promotion and disease prevention. They contain bioactive components such
as peptides, fatty-conjugated linoleic acid (CLA) and oligosaccharides, among others. Whey
proteins and bioactive peptides that are released by hydrolysis may have beneficial biological
effects on the body, such as antioxidant and anti-hypertensive effects [14].
There has been increasing interest over the last decade in CLA, which is mainly found in dairy
products from ruminants. Numerous health benefits have been attributed to CLA such as anticar-
cinogenic, anti-atherogenic, antidiabetic, anti-inflammatory, antioxidant and immunomodulatory
effects based on studies involving cell lines, animal experimental models [15–17] and modulation
of the immune response in patients with Crohn’s disease [18]. Furthermore, 500 mg/kg/d of goat
milk oligosaccharides [19,20] shows promise for reducing intestinal inflammation.
In fact, goat milk oligosaccharides have been shown to exhibit significant intestinal anti-
inflammatory effects in experimental models of mouse colitis [19,20]. Recently, we published a
study showing that the oral administration of goat milk and goat yogurt before and after the
induction of colitis by acetic acid ameliorated intestinal inflammation in rats [21].
Thus, the aim of this study was to assess the effects of goat whey on intestinal inflammation
induced by 2,4-dinitrobenzenesulfonic acid (DNBS) in mice and the cellular responses in the
Raw 264 and CMT-93 cell lines.
Materials and methods
Ethics
This study was conducted in accordance with the Guide for the Care and Use of Laboratory
Animals (NIH Publication No: 85–23, revised 1985), and the protocol was approved by the
Ethics Committee on Animal Experimentation of the University of Granada (Spain) (Ref. No.
EAEC: 2010–286).
Collection and characterization of goat whey
The milk was obtained from crossbred Pardo-Alpine goats over approximately 50 (±10) days
of lactation. The animal diet followed the recommendations of the NRC (2007) and met the
nutritional requirements for lactating goats.
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The milk was collected at the Experimental Unit of São João do Cariri—PB belonging to
the Federal University of Paraı́ba (UFPB, Brazil). The cheese curd used to produce the goat
whey (GW) was prepared in accordance with the protocol developed by Oliveira, Garcia,
Queiroga, and Souza (2012) [22]. The GW was dried using a Buchi Mini Spray Dryer B290
(Büchi Corporation, New Castle, DE, USA).
The following tests were performed in order to characterize the GW: fat was assessed using
a Gerber’s butyrometer, and protein was assessed by the micro-Kjeldahl method according to
the recommendations of the Association of Official Analytical Chemistry (2005). Lactose levels
were assessed using a High Performance Liquid Chromatograph (VARIAN, Waters 26 2690,
California, USA) with a refractive index detector coupled with a Hi-Plex Ca column at 85˚C
using ultrapure water as the mobile phase at a flow rate of 0.6 mL/min. Fatty acids were
extracted (chloroform:methanol:water—2:1:1), and fatty acid composition (including CLA)
was determined by gas chromatography using an Agilent gas chromatograph, model 7890A
(Agilent Technologies, Wilmington, DE, USA), coupled to a Waters Quattro micro GC model
mass spectrometer (Waters Corporation, Milford, MA, USA) [23]. Lastly, the quantification of
sialic acid followed the methodology used by [24].
Reagents
All of the chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless other-
wise stated. The enzyme-linked immunosorbent assay (ELISA) for IL-6 and TNF-α using the
mouse colonic tissue samples was conducted using the starter System1 R&D (Minneapolis,
MN, USA). The colonic RNA tissue was extracted with Trizol1 (Invitrogen Life Technologies,
Life Technologies, Thermo Fisher Scientific Inc., Waltham, MA, USA). Oligo (dT) primers,
Taq1 DNA polymerase (Promega, Madison, WI, USA), and KAPA SYBR1 FAST qPCR
Master Mix (Kapa Biosystems, Wilmington, MA, USA) were used for the real-time quantita-
tive polymerase chain reaction (RT-qPCR) analysis. The polyclonal goat antibodies against
SOCs-1, iNOS, IL-17, NF-κB p65 and p38 MAPK were purchased from Santa Cruz Biotech-
nology (Interprise, Brazil). The streptavidin-HRP-conjugated secondary antibody and the Tre-
kAvidin-HRP Label + Kit were purchased from Biocare Medical (Dako, USA).
Experimental design of the colitis model
Male CD1 mice (30 ± 2.0 g) were supplied by the Laboratory Animal Service of the University
of Granada (Granada, Spain) and housed in the Animal Facilities of the Center of Biomedical
Investigation of the University of Granada (Granada, Spain). They were housed (6 animals per
box) in standard conditions (light/dark cycle of 12 h, temperature 22 ± 0.1˚C and 50–55%
moisture) with free access to food (AIN-93G diet) and water.
The mice were distributed into three groups (n = 12/group): healthy, DNBS control and
mice treated with GW (4 g. kg-1/day, dissolved in 100 μL of water). The healthy and DNBS
control groups received the vehicle (water) only. GW was administered orally for 12 days, 1
hour before colitis induction and 4 days after (S1 Fig).
The induction and assessment of colitis
On the 13th day, colonic inflammation was induced in the DNBS control group and the group
treated with GW (S1 Fig). The animals were fasted for 12 hours and anaesthetized with intra-
peritoneal injections of ketamine (Ketamidor1, Richter Pharma AG, Wels, Germany) (100
mg/kg) and xylazine (Xilagesic1 2%, Calier, Barcelona, Spain) (7.5 mg/kg). The mice were
then administered DNBS (2.5 mg dissolved in 100 μl of 50% ethanol) using a 4-cm intracolonic
catheter (n˚ 6) [25]. They were maintained in a downright position until recovery from
Intestinal anti-inflammatory effects of goat whey
PLOS ONE | https://doi.org/10.1371/journal.pone.0185382 September 28, 2017 3 / 19
anaesthesia. The body weight, incidence of diarrhoea, and water and food consumption were
monitored daily throughout the experiment.
Disease development was assessed using the Disease Activity Index (DAI), which considers
three parameters: weight loss, stool consistency and either blood in the perianal region or
occult blood in the stool (Feca-cult 1Inlab kit). The animals were anesthetized and euthanized
by cervical dislocation on the 17th day of the experiment (S1 Fig).
The colon was then removed aseptically and washed with saline solution (0.9%), and the
weight and length (from the ileocecal junction to the anal margin) were measured to calculate
the weight/length (W/L) ratio.
Explants
Once the colon was opened longitudinally, 3 intestinal explants (3 mm of diameter) were
obtained and incubated at 37˚C in 1 mL of Roswell Park Memorial Institute (RPMI)-1640 cul-
ture medium containing 4.5 g/L glucose supplemented with 10% (v/v) foetal bovine serum, 1%
penicillin/streptomycin, 1% amphotericin and 2% glutamine in a 5% CO2 atmosphere.
The explants were cultured overnight and then collected and the medium was transferred
to Eppendorf tubes and centrifuged at 4000 g for 10 min at 4˚C and frozen until cytokine mea-
surements. The supernatants were collected and kept at -80˚C until levels of the cytokines IL-6
and TNF-α were determined by Enzyme-Linked Immunosorbent Assay (ELISA) using kits
from R&D Systems (Minneapolis, MN, USA) following the manufacturer’s protocols. The
results are expressed as the concentration of cytokine (pg/mL).
Analysis of gene expression in colon samples by RT-qPCR
The colon samples were stored in RNAlater1 for total RNA isolation. TRIzol1 was used for
RNA extraction following the manufacturer’s instructions. All of the RNA samples were quan-
tified with a NanoDropTM 2000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham,
MA, USA), and 2 μg of RNA was reverse transcribed using oligo(dT) primers (Promega,
Madison, WI, USA). Real-time quantitative PCR amplification and detection were performed
in optical-grade 48-well plates in an EcoTM PCR Real-Time Optical System (Illumina, San
Diego, CA, USA) using 20 ng of cDNA, KAPA SYBRs FAST qPCR Master Mix (Kapa Biosys-
tems, Wilmington, MA, USA) and specific primers at a concentration of 10 μM (S1 Table).
The thermal cycling program consisted of DNA polymerase activation for 2 min at 95˚C, fol-
lowed by 40 reaction cycles as follows: denaturation, 8 s (95˚C); annealing, 20 s (at the particular
annealing temperature (Ta) for each pair of primers); and extension, 5 s (80˚C). Fluorescence
was measured at the end of the annealing period of each cycle to monitor the progress of amplifi-
cation, and a dissociation curve (or melt curve) was added to confirm the amplification specificity
of the signal for each case. The gene expression of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was measured and used to normalize the mRNA expression. The relative RNA levels
were calculated using the ΔΔCT method (a comparison of the Ct values of the sample gene and
normalizing gene)—ΔΔCT = ΔCTsample- ΔCTreference.
Histopathological evaluation
Colon samples were collected and fixed in buffered paraformaldehyde (10% in PBS, pH 7.2)
for 24 hours. Cross sections were selected and embedded in paraffin. Tissue sections (5 μm,
n = 5) were taken and stained with haematoxylin and eosin for histological evaluation by opti-
cal microscopy. The criteria for determining the microscopic damage (degree of leukocyte
infiltration and the presence/absence of indicators of the inflammatory process) were evalu-
ated by a pathologist [26].
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Myeloperoxidase (MPO) activity
MPO activity was measured according to the technique described by Krawisz et al. [27], and
the results were expressed as MPO units per gram of wet tissue; one unit of MPO activity was
defined as that degrading 1 mmol hydrogen peroxide/min at 25˚C.
Immunohistochemical analysis of iNOS, p38 MAPK, NF- κB p65 and
SOCs-1
Thin colon sections (3 μm, n = 5) were taken, transferred to silanized slides (Dako, Glostrup,
Denmark) and subjected to deparaffinization and hydration processes. The intestinal tissue was
then washed with 0.3% Triton X-100 in phosphate buffer, treated with 3% hydrogen peroxide,
and incubated overnight at 4˚C with the following primary antibodies: iNOS, 1:500, p38 MAPK,
1:400, NF-κB p65, 1:100 and SOCS-1, 1:800 (Santa Cruz Biotechnology, Interprise, Brazil). After
the slices were washed with phosphate buffer, they were incubated with a streptavidin-HRP-con-
jugated secondary antibody (Biocare Medical, Concord, CA, USA) for 30 min. Immunoreactiv-
ity was visualised with a colourimetric-based detection kit following the protocol provided by
the manufacturer (TrekAvidin-HRP Label + Kit from Biocare Medical, Dako, USA) [28].Known
positive and negative controls were included in each batch using planimetry microscopy (Olym-
pus BX50, Morphology Department/ UFRN) with a high-powered lens (40x). Immunostaining
intensity was determined, and the following scores from 1 to 4 were given: 1, absence of positive
cells; 2, small number of positive cells or isolated cells; 3, moderate number of positive cells; 4,
large number of positive cells. Labelling intensity was evaluated by two previously-trained exam-
iners in a double-blind fashion. Three sections were evaluated per animal.
Confocal immunofluorescence analysis
Three tissue sections (n = 5) were deparaffinised with xylene and washed with various concen-
trations of ethanol and PBS. Antigen retrieval was performed with 10 mM sodium citrate and
0.05% Tween 20 for 40 min at 95˚C, while 0.1% Sudan black in 70% ethanol for 40 min at
room temperature was used to reduce the autofluorescent background. Sections were incu-
bated overnight with primary antibodies (IL-17, 1:400 and ZO-1, 1:100, Santa Cruz Biotech-
nology, Interprise, Brazil) and then washed three times in PBS/0.2% Triton X-100 for 5 min
and incubated with Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (1:700 in
1% BSA) and DAPI (Sigma Chemicals) [29].
In vitro studies
The murine Raw 264 macrophages and CMT-93 rectal carcinoma cell lines were obtained
from the Cell Culture Unit of the University of Granada (Granada, Spain). Cells were cultured
at 37˚C in high glucose (4.5 g/L) modified RPMI-1640 supplemented as described before in a
5% CO2 atmosphere. Both cell lines were sub-cultured and used after exponential growth.
Cells were seeded onto 96-well plates and incubated with various concentrations of GW
(0.1, 1.0, 10, and 100 μg/mL). After 2 h, Raw 264 and CMT-93 cells were stimulated with lipo-
polysaccharides (LPS) from Escherichia coli O55:B5 (100 ng/mL and 10 μg/mL, respectively)
for 24 and 72 h, respectively.
Supernatants from Raw 264 cells were collected after 24 h, and nitrite levels were measured
by the Griess reaction (1% sulphanilamide, w/v, in 5% phosphoric acid and 0.1% N-1-naphthyl-
ethylenediamine, w/v, in water) [30]. The photometric absorbance at 550 nm was determined
to assess nitrite concentration [31]. CMT-93 supernatants were collected after 72 h of stimula-
tion, and IL-6 levels were evaluated by ELISA.
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Statistical analysis
The results are expressed as the mean ± SEM. Differences between the means were tested
using one-way analysis of variance (ANOVA) and Tukey’s test. Analyses were performed
using GraphPad 6.0 (GraphPad Software Inc., La Jolla, CA, USA), and statistical significance
was set at P < 0.05.
Results
Chemical characterization of goat whey
The chemical analysis of GW including protein, total lipid, fatty acid, lactose and oligosaccha-
ride contents is presented in Table 1. Among the fatty acids found in GW, there was 1.92
g.100g-1 of saturated fatty acids (22.21% stearic acid—C18: 0), 0.63 g.100g-1 of monounsatu-
rated fatty acids (vaccenic C18: 1n7 and oleic Z C18: 1n9) and 0.01 g.100g-1 of poly-unsatu-
rated fatty acids (Z linoleic C18: 2n6) from total lipids (2.56 ± 0.16 g.100g-1).
Effects of goat whey on intestinal inflammation
Treatment with GW had protective effects on the intestinal inflammation induced by DNBS in
mice. Rectal administration of DNBS triggered the development of an intestinal inflammatory
process that was characterized by weight loss, changes in stool consistency and blood in the
Table 1. Composition of goat whey (GW).
Components Goat Whey
Protein (g. 100g-1) 5.96 ± 0.30
Total lipids (g. 100g-1) 2.56 ± 0.25
Fatty acids (g. 100g-1)
Undecylic acid (C11:0) -
Lauric acid (C12:0) 0.02
Tridecylic acid (C13:0) -
Myristic acid (C14:0) 0.11
Myristoleic acid (C14:1) -
Pentadecylic acid (C15:0) 0.01
Palmitic acid (C16:0) 1.20
Palmitoleic acid (Z C16:1n9) 0.00
Margaric acid (C17:0) 0.01
Cis-10-Heptadecenoic (C17:1) -
Stearic acid (C18:0) 0.57
Elaidic acid (C18:1n9) -
Oleic acid (C18:1n9) 0.32
Vaccenic acid (C18:1n7) 0.31
Linoleic acid (C18:2n6) 0.01
Arachidic acid (C20:0) -
Linolenic (C18:3n3) -
Heneicosylic acid (C21:0) 0.00
Lactose (g. 100g-1) 15,62 ± 1.08
Oligosaccharides
Acids (mg/L) 66.63 ± 2.34
N-Acetylneuraminic acid (mg/L) 24.91 ±1.54
N-Glycolylneuraminic acid (mg/L) 41.72 ± 0.80
https://doi.org/10.1371/journal.pone.0185382.t001
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perianal region observed on the DNBS control group which had higher DAI values (P < 0.05)
than the treated and healthy groups. The mice treated with GW experienced a recovery of the
DAI (P < 0.05), on the other hand the DAI of the healthy group was scored as zero (0) and
does not appear in the graph bars (Fig 1A).
The W/L ratio of the colon is considered to be an important parameter for the evaluation of
intestinal inflammation. The shortening and thickening of the walls of the colonic tissue are
common symptoms of intestinal inflammation, and we observed higher values for W/L in the
DNBS control group than in the other groups (P< 0.05) (Fig 1C). The colonic damage can be
seen in Fig 1D, where a shortening of the colon and the presence of faeces with a less solid con-
sistency and a darker colour were observed when compared with the treated and healthy
groups.
The intra-rectal administration of DNBS promoted an intestinal inflammatory process that
was characterized by an altered immune response. Various pro-inflammatory cytokines such
as IL-1β, IL-17, IL-6 and TNF-α were up-regulated, as well as other key inflammatory players
such as iNOS, MMP-9 and ICAM-1, and NF-κB p65 and p38 MAPK signaling pathways.
However, the expression of SOCs-1 was down-regulated (P< 0.05) compared with the other
groups.
GW treatment improved the inflammatory status of the colon, as shown by the assessment
of these parameters. Colonic explants from the GW-treated mice produced significantly lower
levels of the pro-inflammatory cytokines IL-6 and TNF-α in comparison with the DNBS con-
trol group (P< 0.05) (Fig 2).
Furthermore, the gene expression of all of the pro-inflammatory markers assayed was sig-
nificantly down-regulated by the treatment (P < 0.05 vs. DNBS control), and the values were
similar to those of the healthy group (P> 0.05) (Fig 3 and S2 Fig).
DNBS-induced colitis was also characterized by an impairment of intestinal barrier func-
tion, as observed by evaluation of the different markers involved in the maintenance of
Fig 1. Effects of goat whey on the experimental model of colitis induced by 2,4-dinitrobenzene
sulfonic acid (DNBS). (A) Disease Activity Index (DAI); (B) food consumption; (C) weight/length ratio of the
colon; and (D) colonic segment of the experimental groups. Data are expressed as the mean ± SEM (n = 12/
group). Groups with different letters or with an asterisk (✶) differ significantly (one-way ANOVA post hoc
Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g001
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epithelial integrity such as the mucins MUC-2 and MUC-3, occludin, and ZO-1 (Fig 4 and S2
Fig). Treatment with GW also up-regulated the expression of these key proteins compared
with the DNBS control group (P< 0.05), which was similar to the healthy group (P> 0.05).
Fig 2. Effects of goat whey on pro-inflammatory cytokines as measured by ELISA. Distal colon tissue
samples were cultured overnight. The supernatants were assessed for cytokine levels using kits from R&D
Systems (Minneapolis, MN, USA) following the manufacturer’s protocols. The cytokine levels in the
supernatant were expressed as the concentration in pg/mL. (A) Interleukin (IL)-6 and (B) tumour necrosis
factor (TNF)-α production in colonic tissues from mice with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced
colitis. Data are expressed as the mean ± SEM (n = 12). The groups with different letters are significantly
different (one-way ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g002
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Cellular ZO-1 labelling (green) was strong in the GW group (Fig 4E.3), moderated in the
healthy group (Fig 4E.1) and almost absent in DNBS control (Fig 4E.2). Densitometric analysis
confirmed that there were significantly increased ZO-1 immunoreactivities in GW group
(P< 0.05), relative to the DNBS control group. These results showed that an increased expres-
sion of ZO-1 corresponds to lower destruction of the intestinal barrier that preserves gut
permeability.
Histological assessment of the colon specimens from the DNBS control group showed
moderate leukocyte infiltration, a loss of tissue architecture with consequent destruction of
the epithelium, a reduction in goblet cells and the presence of haemorrhages (Fig 5B). GW
reduced colonic inflammation, thereby preserving the mucosal histology and decreasing neu-
trophil infiltration (P< 0.05 vs. DNBS control group) (Fig 5C). The colons of the healthy
group appeared normal with full organ preservation and the absence of inflammation (Fig
5A).
A reduction (P< 0.05) of the microscopic score (Fig 5D and S2 Fig) in the GW group was
followed by a significant reduction (P < 0.05) of the MPO activity (Fig 5E and S2 Fig) com-
pared to the DNBS control group.
The results of our immunohistochemical evaluation of the colonic sections were in agree-
ment with the previous results because they showed that DNBS up-regulated the expression of
the pro-inflammatory mediator iNOS, which was reduced after the treatment. Moreover, the
levels of the inflammatory modulator SOCs-1 were diminished in the DNBS control group
and normalized in the GW group (P < 0.05) (Fig 6 and S2 Fig).
NF-κB p65 and p38 MAPK are important signaling pathways in experimental and human
colitis. Immunohistochemical staining showed inhibition of these pathways in the anti-inflam-
matory effect of GW on colitis.
Fig 3. Effects of goat whey on the gene expression of pro-inflammatory cytokines as measured by RT-
qPCR. Colonic gene expression of the pro-inflammatory cytokines (A) Interleukin (IL)-1β, (B) IL-6, (C) tumour
necrosis factor (TNF)-α, (D) inducible nitric oxide synthase (iNOS), (E) matrix metalloproteinase (MMP)-9, and
(F) intercellular adhesion molecule (ICAM)-1 analyzed by real-time qPCR and normalized with the housekeeping
gene, Glyceraldehyde-3-phosphate dehydrohenase (GAPDH) in dinitrobenzene-sulphonic acid (DNBS) mice
colitis 4 days after damage induction. Data are expressed as the mean ± SEM (n = 12/group). The groups with
different letters are significantly different (one-way ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g003
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As shown in Fig 6C.2 and 6D.2, DNBS activated the expression NF-κB p65 and p38 MAPK
(P< 0.05), respectively, in the colonic tissue, compared to the healthy group (Fig 6C.1 and
6D.1). However, treatment with GW significantly reversed this effect (Fig 6C.3 and 6D.3), rep-
resented by a marked reduction in the expression of NF-κB and MAPK 38 (P < 0.05) in rela-
tion to the DNBS control group. The immunohistochemistry scores can be visualized in Fig
6E.3 and 6E.4. These results corroborate data from the proinflammatory cytokines IL-1β, IL-6
and TNF-α.
The IL-17 signal was strongly diffused (green) in the cells of the DNBS-control group (Fig
7A.2), weak to moderately diffused (green) in all mucosal layers of the GW group (Fig 7A.3),
and weak to absent (green) in the healthy group (Fig 7A.1). An increase in the labelling of
DAPI showing a decrease in the labelling of IL-17 was observed in the treated and healthy
Fig 4. Effects of goat whey on gene expression by RT-qPCR and immunofluorescence of the
intestinal mucosal barrier proteins as measured. Colonic gene expression of the barrier function
mediators gene expression (A) Mucin (MUC)-2, (B) MUC-3, (C) occludin, (D) zonula occludens (ZO)-1
analyzed by real-time qPCR and normalized with the housekeeping gene, Glyceraldehyde-3-phosphate
dehydrohenase (GAPDH) in dinitrobenzene-sulphonic acid (DNBS) mice colitis 4 days after damage
induction. Representative confocal photomicrographs of ZO-1 (E) immunoreactivity (green) in colons of the
animals from each group; the sections are nuclear counterstained with DAPI (blue): (E.1) Healthy group had
moderated ZO-1 labelling; (E.2) ZO-1 labelling was almost absence in DNBS control group; (E.3) ZO-1
labelling (red arrow) was strong in the treated group with goat whey; (E.4) Densitometric analysis confirmed a
significant increases in ZO-1 in goat whey. Data are expressed as the means ± SEM. the groups with different
letters differ significantly (one-way ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g004
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groups. Densitometric analysis confirmed a significant reduction of IL-17 immunoreactivity
in the GW group (P < 0.05) (Fig 7A.4 and S2 Fig).
Effects of goat whey on cellular responses
To characterize the anti-inflammatory effects of the GW components observed in the animal
studies, in vitro studies were also conducted using two cell types that are involved in the
immune response, Raw 264 macrophages and intestinal epithelial CMT-93 cells.
Fig 5. Effects of goat whey on the colonic mucosa of colitic mice as assessed by histological
examination. Sections of the colonic mucosa were stained with haematoxylin and eosin (x100): (A) Healthy,
(B) DNBS control, and (C) Goat Whey. (D) Microscopic scores were assigned to the different groups
according to the criteria described by Zea-Iriarte et al. (1996) [26] and (E) Myeloperoxidase activity–MPO.
Data are expressed as the means ± SEM (n = 12/group), and the groups with different letters differ
significantly (one-way ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g005
Fig 6. Immunohistochemical analysis of colonic tissue from mice with 2,4-dinitrobenzene sulfonic acid
(DNBS)-induced colitis. Effects of goat whey on suppressor of cytokine signalling-1 (SOCs-1) (Panel A),
inducible nitric oxide synthase (iNOS) (Panel B), NF-kappaB (NF-κB) p65 (Panel C) and p38 Mitogen Activated
Protein Kinases (MAPK) (Panel D). For each antigen, three immunostained sections were examined per animal
(n = 5, 3 sections per animal). 40 x magnification, scale bar = 100 μm; 1: Healthy; 2: DNBS Control; 3: Goat
Whey; Arrow [⇩] = moderate marking; arrow and star [⇩$] = strong marking; star [$] = weak to moderate
marking. Panel E (Immunohistochemical score)—E.1: SOCs-1; E.2: iNOS; E.3: NF-κB p65; E.4: p38 MAPK.
Data are expressed as the means ± SEM; the groups with different letters differ significantly (one-way ANOVA
post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g006
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Although GW stimulated NO production in Raw 264 cells at higher concentrations (10 and
100 μg/mL) (P < 0.05 vs. unstimulated untreated cells), after LPS stimulation, GW signifi-
cantly reduced NO production (P< 0.05 vs. untreated LPS-stimulated cells) (Fig 8A).
In CMT-93 cells, GW had no effect on IL-6 production (P > 0.05 vs. untreated unstimu-
lated cells), but when the cells were stimulated with LPS, GW reduced the production of this
cytokine at all concentrations assayed (P < 0.05 vs. untreated LPS-stimulated cells) (Fig 8B).
GW did not affect cell viability at any of the concentrations assayed (data not shown).
Discussion
The results of this study show that GW has preventive effects on DNBS-induced intestinal
inflammation in mice, revealing its potential as a functional food that could be useful for the
management of human IBD.
Assis et al. (2016) [21] reported a significant improvement in intestinal inflammation in a
rat model of acetic acid-induced experimental colitis after treatment with goat milk and goat-
derived probiotic yogurt, as evidenced by reductions in macroscopic damage, inflammatory
infiltration and oxidative stress, as well as improvements in the cytoarchitecture of the colon.
GW improved the clinical signs related to DNBS-induced damage that were evaluated by the
DAI. In this regard, GW reduced diarrhoea, weight loss and the presence of blood in the peria-
nal region or occult blood in the stool, as well as the intestinal macroscopic damage and
weight/length ratio. The anti-inflammatory activity of GW could be attributed, at least in part,
to the presence of polyunsaturated fatty acids and isomers of CLA, such as vaccenic acid and
oligosaccharides. Linoleic acid plays an important role in the composition of fatty acids in
milk. After the action of the Δ-9 desaturase enzyme, it forms oleic acid, vaccenic acid and
Fig 7. Effect of goat whey on IL-17 expression in colitic mice. Representative confocal photomicrographs
of IL-17 (Panel A) immunoreactivity (green) in colons of the animals from each group; the sections are nuclear
counterstained with DAPI (blue): (A.1) Healthy group had absent or weak IL-17 labelling in all mucosa layers;
(A.2) IL-17 labelling was strong in the DNBS control group; (A.3) weak to moderate IL-17 labelling (red arrow)
was seen in the group treated with goat whey; (A.4) Densitometric analysis confirmed a significant reduction
in IL-17 immunoreactivity in goat whey. Data are expressed as the means ± SEM; the groups with different
letters differ significantly (one-way ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g007
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rumenic acid, which are also referred to as conjugated linolenic acids (CLAs) [32]. In total, 60
to 95% of the CLA found in milk fat is derived from the action of this enzyme [33]. Interest-
ingly, a recent study reported that feeding with CLA-enriched milk fat, 2% (wt/vol), was effec-
tive in reducing the levels of the pro-inflammatory markers of experimental chronic colitis in a
mouse model of dextran sulphate-induced colitis [34].
Oligosaccharides are glycans that are composed of lactose with branches of N-acetyllactosa-
mine with sialic acid and fucose on their chains. Sialic acid reduces the adhesion of leukocytes
to endothelial cells, indicating that human milk oligosaccharides may have immuno-regula-
tory effects [35,36]. In addition, oligosaccharides have the ability to stimulate the growth of
bifidobacteria in the gastrointestinal tract and beneficial intestinal microbiota in the colon, as
well as stimulate the immune system and participate in the defence against bacterial and viral
infections by acting as competitive inhibitors of binding sites on the intestinal surface [37,38].
In milk from Saanen and Garganica goats, the levels of sialyl oligosaccharide 3-sialyllactose,
6-sialyllactose and disialyllactose were decreased during days 0–90 of lactation. For Saanen
goats, the levels of 3-sialyllactose varied from 176.2 to 106.1 mg/L, while the levels of disialyl-
lactose varied from 146.9 to 27.4 mg/L (Claps et al., 2016). Thum et al. (2015) [39] showed that
Fig 8. Effects of goat whey on cell lines. (A) Nitrite (NO) production and (B) interleukin (IL)-6 levels in Raw 264
and CMT-93 cells, respectively, in basal or LPS-stimulated conditions (100 ng/mL and 1 μg/mL, respectively).
Data are expressed as the mean ±SEM. The bars with different letters are significantly different (one-way
ANOVA post hoc Tukey’s test, P < 0.05).
https://doi.org/10.1371/journal.pone.0185382.g008
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milk and whey obtained from Saanen goats in New Zealand had high concentrations of sialyl-
oligosaccharides (0.20 g/L), suggesting that it may be a useful source to explore the potential
health benefits in trials with human. Despite the lower amounts of oligosaccharides, especially
sialic acid, in goat milk compared with human milk, they are present at considerable amounts
when compared to other ruminants and could be considered as a potential substitute [40,41].
In this study, goat whey reduced the levels of pro-inflammatory cytokines (IL-1β, IL-6 and
TNF-α), which could be attributable to the presence of CLA and oligosaccharides. The reduc-
tion of IL-6 and TNF-α levels by treatment with GW was also confirmed in ex vivo assays
using colonic explants. The elevated expression of IL-1β, IL-6 and TNF-α plays a key role in
the pathogenesis of human IBD and experimental colitis [4].
According to previous reports, the expression of proinflammatory cytokines IL-1, IL-6 and
TNF-α is mediated by intracellular signal transduction involving the NF-κB pathway and the
activation of MAPKs (p38, ERK and JNK) [6]. Once activated, NF-kB also regulates cell prolif-
eration and survival as well as the expression of adhesion molecules (i.e., ICAM) and growth
factors, which impact the length and duration of intestinal inflammation. Thus, according to
the results obtained we can infer that GW exerts intestinal anti-inflammatory activity through
the inhibition of the NF-kB p65/ p38 MAPK signaling pathway.
IL-6 is best described as a pro-tumorigenic cytokine, and together with other members of
this family, it affects cell proliferation, survival, differentiation and migration [42], which
includes an important role in the pathogenesis of IBD in human and murine by Th1; therefore,
reduced IL-6 production is considered to be useful in treating colitis [43,44].
Moreover, inhibition of IL-6 in patients with IBD not only reduces intestinal inflammation
but also decreases the risk of developing colorectal cancer [45]. GW induced an inhibitory
effect on IL-6 secretion in LPS-stimulated CMT-93 cells. We emphasize that there was no posi-
tive regulation of IL-6 production from CMT-93 cells. This finding is supported by the in vivo
experiments in which the improvement of murine colitis was also associated with a down-reg-
ulation of IL-6 gene expression in colonic tissue.
The mechanisms of modulation of the gene expression of inflammatory proteins include
down-regulation of the signalling cytokines and STAT receptors such as the endogenous pro-
tein SOCs [46,47]. In this regard, GW treatment promoted an increase in SOCs-1, which may
be associated with the reduction in the levels of pro-inflammatory cytokines.
GW also caused a reduction in ICAM-1 levels that may be a result of the improvement in
intestinal inflammation. In the intestinal inflammatory process, cells and macrophages can
release large amounts of TNF-α. This can increase the expression of adhesion molecules such
as VCAM-1 and ICAM-1 in endothelial cells, thereby significantly increasing the infiltration
of leukocytes into the intestinal mucosa. It has been shown that blocking one or more of these
adhesion molecules can effectively inhibit inflammation, which makes them interesting targets
for the development of new therapies [48].
IL-17 is also an attractive therapeutic target, as it is involved in the development of chronic
inflammation associated with many inflammatory and autoimmune disorders when produced
in excess. As expected, the IL-17 staining was more pronounced in the confocal analysis of the
DNBS control group compared with the other groups. However, at lower concentrations, IL-
17 plays a key role in host defence against extracellular bacterial and fungal infections [49].
The beneficial effects of GW were also evidenced in the histopathological evaluation of the
colonic segments and in the reduction of MPO activity, an important marker of neutrophil
infiltration. We observed an improvement in the tissue architecture and an increase in the
number of goblet cells, which are important components of the intestinal epithelium that are
responsible for producing key peptides for defence and epithelial repair of the intestinal
mucosa.
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The presence of goblet cells in colonic tissue from animals treated with GW corroborates
the above data concerning MUC-2 and MUC-3 regulation. Goblet cells synthesize glycopro-
tein-secreting mucins (MUC-2) and mucins that are linked to the epithelial membrane
(MUC-1, MUC-3), thus protecting the underlying epithelial cells from mechanical damage
and the direct actions of ingested chemicals by maintaining the integrity of the intestinal bar-
rier [50–52].
The intestinal epithelium is formed by a cell monolayer that acts as a barrier and is con-
nected with sophisticated cellular junctions, among them occludin and ZO-1 [53]. The up-reg-
ulation of these proteins is related to improvements an intestinal permeability [54] and
epithelial integrity, as it prevents the bacterial translocation of input antigens and subsequently
reduces colitis [55]. GW also promoted a reduction in MMP-9, a family of proteolytic zinc
enzymes and calcium-dependent structural proteins that degrade the extracellular matrix and
are implicated in the pathogenesis of human IBD and experimental colitis [56].
In addition, iNOS has also been shown to be involved in the pathogenesis of bowel inflam-
mation because an increase in iNOS expression in areas of inflammation has been shown to
be associated with histological inflammatory parameters [57]. It has been proposed that the
increased amounts of NO produced by iNOS can react with superoxide to form peroxynitrite,
which induces deleterious changes in the structure and function of proteins [58]. Thus, the
reduction in iNOS gene expression in the group treated with GW may be associated with
improvements in the inflamed areas of the colons of these mice. Moreover, the in vitro studies
performed in Raw 264 cells, both under basal conditions and after stimulation with LPS (thus
simulating an inflammatory environment), were aimed at assessing whether the anti-inflam-
matory activity of GW was related to inhibition of iNOS enzyme.
The fact that pretreatment of these cells with the highest concentrations of GW resulted
in an increase in NO production may indicate that GW activates constitutive nitric oxide
synthase (cNOS). In this case, the production of large amounts of NO may be important for
protecting against cellular invaders and cell tumours, as well as having beneficial effects on vas-
cular lesions with endothelial cell loss [59]. However, GW decreased nitric oxide production
in cells stimulated with LPS, and LPS can directly interact with the apical surface to induce
responses in intestinal epithelial cells, which in turn induce the production of cytokines and
other inflammation mediators [43].
Conclusion
GW has revealed itself as a promising candidate for the treatment of IBD. It was able to miti-
gate the evaluated clinical signs and inhibit the secretion of pro-inflammatory cytokines such
as IL-1β, IL-6, IL-17 and TNF-α, through the inhibition of the p38 MAPK/NF-kB p65 signal-
ling pathways, as well as the reduction of iNOS, MMP-9 and ICAM-1, in particular by altering
the proprieties of CLA and sialic acid. Moreover, GW increased the expression of the mucins
MUC-2 and MUC-3, as well as occludin, ZO-1 and SOCs-1, thus inhibiting the intestinal
inflammatory process induced by DNBS. A reduction in inflammation was also evidenced by a
decrease in the microscopic damage score of the colonic tissue from the GW-treated group.
GW also modulated the effects of iNOS in vitro by reducing nitrite production in Raw 264
cells that were stimulated with LPS, as well as IL-6 production in CMT-93 cells.
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Methodology: Daline F. S. Araújo, Yasmim R. F. Sousa, Francesca Algieri, Maria Elena Rodri-
guez-Cabezas.
Project administration: Rita de Cássia R. E. Queiroga.
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57. Palatka K, Serfőző Z, Veréb Z, Hargitay Z, Lontay B, Erdődi F, et al. Changes in the expression and dis-
tribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflamma-
tory bowel disease. Scand J Gastroenterol. 2005;40: 670–680. doi:10.1080/00365520510015539
58. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric
oxide synthase activity. Gut. 1995;37: 247–55. doi:10.1136/gut.37.2.247
59. Kuo PC, Schroeder R a. The emerging multifaceted roles of nitric oxide. Ann Surg. 1995;221: 220–35.
doi:10.1097/00000658-199503000-00003.
Intestinal anti-inflammatory effects of goat whey
PLOS ONE | https://doi.org/10.1371/journal.pone.0185382 September 28, 2017 19 / 19
